Concept selection in the development of medical devices: the case of the smart stent-graft by Isa C.T. Santos et al.
 1 Copyright © 2010 by ASME 
Proceedings of the 2011 Design of Medical Devices Conference 
DMD2011 
April 12-14, 2011, Minneapolis, MN, USA 
DMD2011-5227 
CONCEPT SELECTION IN THE DEVELOPMENT OF MEDICAL DEVICES: 
THE CASE OF THE SMART STENT-GRAFT 
 
 
Isa C.T. Santos1 and João Manuel R. S. Tavares 
Faculty of Engineering, University of Porto / 
Institute of Mechanical Engineering and Industrial Management 
Porto, Portugal 
1
 contact author 
 
 
Luís A. Rocha 
Institute for Polymers and Composites / I3N, University of Minho 
Guimarães, Portugal 
 
 
ABSTRACT 
During product development, ideas are narrowed down to a 
single one by the designers in order to satisfy the customers’ 
needs. This process is called concept selection and is crucial to 
the development of new products because, from this point 
onward, the design team is committed to a concept whose 
modification implies delays and additional costs. 
Decisions made during the concept selection phase are 
often difficult due to the uncertainty caused by the lack of 
objective data. However, it is possible to reduce this uncertainty 
assessing each concept’s expected costs and benefits. 
Medical devices, before entering the market, are 
scrutinized by several agencies around the world to assess their 
clinical- and cost-effectiveness. In order to reduce the 
uncertainty associated with concept selection, the parameters 
evaluated by the multiple agencies should be used to support 
the idea to pursue. However, as that data is not available yet, in 
this paper, several parameters are identified to evaluate each 
concept and, for each metric, the most adequate measurement 
technique is described. This paper also presents a specific 
implementation of the design process for a new stent-graft. 
INTRODUCTION 
Product development refers to the process of creating 
products with new or different characteristics to offer fresh or 
additional features to customers. While some authors describe 
this process with only 5 steps, others name as many as 25 
stages [1]; here, the design process is divided in 8 steps, Figure 
1. 
Normally, the development of a product is triggered by a 
need or an idea. Then, the design team identifies the specific 
problems that customers intend to solve purchasing a good or 
service (customer needs) and generate concepts. From the 
panoply of concepts, only one is developed and optimized. 
Following this, prototypes and/or small series are produced. 
These pre-series are evaluated by a restrict number of clients or 
by certifier companies. The process ends with the launch of the 
product in the market. 
In spite of the design process being commonly represented 
in a linear fashion (as shown in Figure 1), the development of a 
product is an iterative process in which different steps can be 
performed simultaneously (i.e. concurrent engineering [2]). 
 
 
FIGURE 1: DIFFERENT STEPS OF THE PRODUCT DEVELOPMENT PROCESS 
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In the design process, concept selection is a vital part 
because from this point onward there is a convergence to a 
detailed solution and, according to the literature, between 60 
and 80% of the cost is committed at this stage [3]. Currently, 
there are multiple concept selection techniques; but, they have 
limitations incorporating uncertainty and do not aim to quantify 
each concept expected cost and benefit [4]. 
Before entering the market, medical devices are scrutinized 
by different agencies around the world, namely the FDA (Food 
and Drug Administration) in the USA, to assess their safety, 
effectiveness and quality [5]. Other agencies, such as NICE 
(National Institute for Health and Clinical Excellence) in the 
UK, perform cost-effectiveness analysis and make 
recommendations to organizations in the public, private, 
voluntary and community sectors on treating specific diseases 
and conditions. In order to reduce the uncertainty associated 
with concept selection, the parameters evaluated by those 
agencies should be used in step 4 of Figure 1 to support the idea 
to pursue. However, in such an early stage of product 
development, data is not available. Nonetheless, other 
parameters can be used to estimate the concept’s expected costs 
and benefits. In this paper, several parameters were identified to 
evaluate each concept for a new stent-graft and, for each 
metric, the most adequate measurement technique was 
described. 
This paper is organized as follows. After an introduction to 
product development and concept selection, the definition of a 
stent-graft is presented along with the description of the disease 
for which it is used. Following this, multiple concepts for a 
stent-graft are described, and the parameters to be evaluated are 
identified as well as their measurement techniques. The paper 
then closes with the main conclusions. 
AORTIC ANEURYSMS AND STENT-GRAFTS 
An aortic aneurysm is a localized blood-filled dilatation of 
the aorta [6] that, if left untreated, may burst or rupture causing 
shock and even death due to massive blood loss. Among its risk 
factors [7], gender and age play an important role, with males 
over 65 years old predominantly at risk. According to the 
Eurostat, currently approximately 16 % of the European 
population is aged 65 or over. Projections estimate that this 
value will boom to more than 28 % in the year 2050, so 
consequently the disease’s incidence is expected to increase as 
well as the demand of more cost-effective treatments. 
Since the early 1950s, the common treatment of aortic 
aneurysms has consisted of an open surgery and the 
replacement of the diseased segment of the aorta by a synthetic 
graft. In the early 1990s, Volodos (in Ukraine) and Parodi (in 
Argentina) demonstrated that endovascular aneurysm repair 
(EVAR) was a safe and feasible procedure suitable to be an 
alternative to open surgery [8]. Presently, published data shows 
that the treatment of this condition is also viable with total 
laparoscopy or assisted laparoscopy [9]. Figure 2 summarizes 
the current management plan for aortic aneurysms. The 
treatment is selected considering the technology available in the 
medical center, the anatomy of the aneurysm, the operative risk 
of repair, the patient’s life expectancy, and the personal 
preferences of the patient. 
 
 
FIGURE 2: FLUXOGRAM FOR THE MANAGEMENT OF AORTIC ANEURYSMS. 
 
EVAR (Figure 3) is a minimally invasive procedure in 
which an endoprosthesis - a stent-graft - is guided from the 
femoral artery to the affected artery segment. The objective of 
this procedure is to shield the aneurysm sac from the blood 
pressure, thus preventing the rupture of the artery wall. 
Although this technique is associated with advantages such as 
shortened hospital stays, accelerated recovery and early return 
to full activity, complications still occur, requiring life-long 
surveillance of patients [10]. Presently, surveillance protocols 
require imaging at 1, 6, and 12 months after the procedure, and 
thereafter on an annual basis [11]. 
 
 
FIGURE 3: DEPLOYMENT SEQUENCE OF A STENT-GRAFT DURING EVAR. 
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When EVAR was introduced, it revolutionized the 
treatment of aortic aneurysms. However, after 20 years of use, 
questions are being raised regarding the follow-up costs [12] 
and alternative approaches are being pursued. 
In order to reduce or even eliminate the need of expensive 
and (potentially) harmful imaging exams, the development of a 
smart stent-graft (a device with sensing capabilities) is being 
considered as an alternative. Such device would include some 
in-device mechanism to collect measurements regarding the 
device’s performance and/or the patient health and can 
communicate with an external element. Other benefits would be 
the reduction of the treatment costs and the improvement of the 
patient’s quality of life. Furthermore, it would provide 
information regarding the behavior of the aneurysm sac after 
the deployment of a stent-graft. 
Although, there are patents [13,14] that propose the use of 
in-device smart elements to check structural integrity of grafts, 
drug delivery and the detection of deposits in a vessel, the 
technology is not commercially available. Thus, it is expected a 
long time before such solutions become a standard. 
DEVELOPMENT OF A NEW DEVICE 
The development of the smart stent-graft began with the 
identification of two needs: improve the performance of the 
existing devices and reduce EVAR’s follow-up costs. 
The customers’ needs were gathered by reviewing the 
literature and conducting surveys of both patients and vascular 
surgeons. However, other techniques, such as interviews, could 
have been used [5,15]. 
The customers’ needs and wants were then classified in 
accordance with the Kano Model [16], Table 1. This model 
classifies product requirements conform to their influence in 
the customers’ satisfaction, Figure 4. The “must-be 
requirements” are basic criteria of the product; if they are not 
fulfilled, customers will not be interested in the product at all. 
With regard to the “one-dimensional requirements”, customers’ 
satisfaction is proportional to the level of fulfillment (the higher 
the level of fulfillment, the higher the customers’ satisfaction 
and vice-versa); usually these requirements are explicitly 
demanded. The attractive requirements are neither explicitly 
expressed nor expected by the customers; fulfilling these 
requirements leads to more than proportional satisfaction, but, 
if they are not met, there is no feeling of dissatisfaction. 
Having in consideration the ranked needs, concepts were 
defined as a group of features that the new device should have 
without referencing the technology necessary to accomplish 
them (Table 2). The first concept refers to a stent-graft 
equivalent to the current ones but with improved performance 
since doctors seek devices with lower profiles and a more 
predictable behavior. Both concepts 2 and 3 introduce smart 
elements; while concept 3 aims to measure flow, the second 
concept measures pressure. Currently, there are no devices 
capable of measuring blood flow, but there are two devices that 
measure pressure inside an aneurysm sac: the Impressure 
Sensor (Remon Medical, Tel Aviv, Israel) and the CardioMems 
EndoSure Wireless AAA Pressure Sensor (CardioMEMS, Inc, 
Atlanta, USA) [11]. The fourth concept corresponds to an ideal 
stent-graft. 
Ideally, the design team would analyze the multiple 
concepts and select one or combine the best features of each 
one creating a new concept. However, since the development 
and approval of a medical device is a long process, the design 
team should consider the possibility of open surgery or 
laparoscopy be improved or a new treatment for aortic 
aneurysm be introduced; in such case, a smart stent-graft would 
no longer be needed. Figure 5 shows the decisions that the 
design team can make. 
 
 
FIGURE 4: KANO’S MODEL OF CUSTOMERS’ SATISFACTION. 
 
TABLE 1: LIST OF NEEDS AND WANTS FOR THE SMART STENT-GRAFT. 
Must-be • Biocompatible and biostable 
• Non toxic, allergic and carcinogenic 
• Not cause thrombosis and hemolysis 
• Not cause inflammatory reaction or foreign body 
reaction 
• Exceed patient life expectancy 
• Flexible, ductile and fatigue resistant 
• Stable configuration 
• Resistant to corrosion, wear and tear 
• Radial force that ensures fixation and avoids 
leaks 
• Radiopaque 
• Sterilizable 
• Storable as an "off-the-shelf" product 
• Manufacture environmentally accepted  
Satisfier • Zero porosity 
• Predictable behavior 
• Wide range of diameters and lengths 
• Low profile 
Delighter • Minimizes flow resistance and pressure drops  
• Indicates the intraluminal pressure (systolic and 
diastolic) 
• Indicates the pressure inside the aneurysm sac at 
several points 
• Indicates if stent-graft migrates 
• Indicates if module disconnects 
• Indicates stent fractures 
• Indicates if graft tears 
• Indicates blood flow 
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TABLE 2: CONCEPTS FOR A SMART STENT-GRAFT. 
Concept 1 Satisfies all “must-be” and “satisfier” attributes 
Concept 2 Satisfies all “must-be” and “satisfier” attributes 
Indicates the pressure inside the aneurysm sac at several 
points 
Concept 3 Satisfies all “must-be” and “satisfier” attributes 
Indicates blood flow 
Concept 4 Satisfies all “must-be”, “satisfier” and “delighter” attributes 
 
 
FIGURE 5: POSSIBLE DECISIONS. 
 
The design team should select the option that provides the 
higher expected value (EV) defined by: 
 
 =  ∙  ∙ ∑ 	 ∙ ∏, (1) 
 
in which p represents the probability of a healthy outcome 
using the device, D the demand, qm quantitative parameters 
that can be expressed in monetary units and ql qualitative 
parameters expressed as scaling factors. 
While the demand and the probability of a healthy outcome 
are independent of the point of view adopted, the patient, the 
health professional and the one that pays may perceive the 
quantitative and qualitative parameters differently. In his work, 
Shah [17] argues that the development of medical devices 
benefits from the involvement of healthcare professionals and 
the ultimate end users. However, they are rarely the ones that 
decide to buy and/or pay for a device. When evaluating the 
concepts for a new medical device, each type of user will 
access the parameters differently. Thus, the expected value 
should be determined for each point of view and the decision 
should consider all of them. 
The main metrics are described below as long with their 
measurement technique. 
PROBABILITY 
This parameter refers to the probability of a healthy 
outcome using the device, i.e. the probability of the device not 
causing complications or not requiring further treatments. In the 
case of a smart stent-graft, this value refers to the probability of 
the patient being free of complications, such as endoleaks, 
stent-graft migration or endotension. 
Using historical data is possible to calculate the probability 
of a healthy outcome. However, this task becomes more 
complicated in the case of devices yet-to-be-developed. Thus, a 
sensitive analysis is likely the best way to understand how the 
decision will be affected. 
DEMAND 
The demand is defined as the quantity requested by the 
consumers and is a function of the disease’s incidence rate and 
the consumers’ ability to pay. The demand of each concept can 
be obtained by analogy, i.e., comparing each concept with the 
demand of devices with similar outputs. 
COST OF THE DEVICE 
The cost of the device refers to the price paid to acquire the 
device, including its disposal. Depending on the type of the 
device, this value can be obtained either by analogy or by using 
a parametric model. 
COST OF THE PROCEDURE 
The cost of the procedure is the price paid for the patient to 
receive the device; it includes every cost from the patient’s 
arrival to his release from the hospital. In the case of a stent-
graft, the cost of the procedure includes the imaging exams 
done to prepare the EVAR, the hospital stay, the operation 
room, the anesthesia and all the healthcare professionals 
involved. 
This cost can be determined using a bottom-up approach 
(engineering buildup), which is a method that sums up all the 
relevant parts. 
COST OF USE / MAINTENANCE 
The cost of use / maintenance refers to the value spent to 
benefit from the device, namely medication and energy. It also 
includes the value spent to restore the device to a specified 
condition. For example, in the case of prostheses like a smart 
stent-graft, this parameter is the cost of the medication to avoid 
a foreign body reaction or the price of a reintervention to repair 
a complication, while the cost of use / maintenance of a 
computed tomography (CT) scan is the sum of the cost of 
energy, the space occupied and the operator. 
Like the cost of the procedure, the cost of use / 
maintenance can be determined using a bottom-up approach. 
FOLLOW-UP COST 
This parameter refers to the value spent to assure the 
proper functioning of the device. 
In the case of a stent-graft, it would include the imaging 
exams required by the follow-up protocol. 
This parameter will be determined using a bottom-up 
approach. 
LOSSES TO THE PATIENT 
Losses to the patient reflect the value lost by the patient 
due to its condition; it includes the expenses that the patient and 
his caregiver incur due to the disease. For example, a patient 
that performed an EVAR has to go regularly to follow-up 
medical appointments; in this case, the losses refer to the work 
hours lost by the patient and his caregiver to attend the 
appointment and perform the exams that will be analyzed in 
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that appointment. It also includes the expenses with 
transportation to and from the appointment. 
This parameter will be determined using a bottom-up 
approach. 
BENEFITS TO THE COMMUNITY 
A smart stent-graft avoids imaging medical exams; thus, 
the equipment can be used to treat and/or diagnose other 
conditions from others in the community. This is an example of 
a benefit to the community. 
This parameter will be determined using a bottom-up 
approach. 
WILLINGNESS TO PAY 
Willingness to pay (WTP) means the maximum amount of 
medical cost a patient is willing to pay to gain benefit or 
prevent any risk in medical care. It may vary, depending on age, 
income, level of education, severity of disease, possibility of 
cure as well as healthcare service and culture. 
WTP is expressed in monetary units. Regarding its 
calculation, the literature has different methods to measure the 
consumers’ hypothetical or actual willingness to pay and 
whether they measure consumer willingness to pay directly or 
indirectly. 
EFFECTIVENESS 
This qualitative parameter measures the degree to which 
the device is successful in producing the desired result and 
reflects whether the device is sufficient to treat the medical 
condition. This parameter is equal to the number of life years 
gained. 
MEDICATION SECURITY 
Medication security reflects if the device has side effects or 
not. This parameter is measured in a scale, with the categories 
being: non-applicable (nominal), safe (benefit) and unsafe 
(detriment). 
RISK 
Risk expresses the probability or threat of a damage, injury, 
liability, loss, or other negative occurrence to both users and 
patients. It will also consider whether the device will represent 
a risk during its manufacture, transport and disposal. Like 
medication security, this parameter is measured in a scale with 
the categories being: neutral (nominal), very low (benefit), low, 
medium, high and very high (detriment). 
QUALITY OF LIFE 
There is an extensive literature about quality of life. In this 
case, quality of life will be defined as the ability to enjoy 
normal life activities. 
RECYCLABILITY 
Recyclability is a qualitative parameter that expresses the 
ability of the device to be captured and separated for 
conversion or reuse. It can be recyclable (benefit), non-
recyclable (detriment) or non-applicable (neutral). 
TECHNOLOGY MATURITY 
The technology maturity reflects where the concept’s 
technology known and used. This parameter is measured in a 
scale, with the categories being: development (detriment), 
introduction (neutral), growth (benefit), maturity (benefit) and 
decline (detriment). 
FLEXIBILITY 
Flexibility refers to the ability of the device to have a 
different application other than the one it was initially 
developed for, that is, to have an off-label use. It can be non-
applicable, yes or no. 
SCIENTIFIC BENEFIT 
This parameter reflects whether the device can contribute 
to a better understanding of the disease in which it is used or 
others diseases. It can either be yes (benefit) or no (neutral). 
CONCLUSIONS 
In order to reduce the uncertainty associated with concept 
selection, multiple parameters were presented to estimate the 
expected value of four concepts for a new smart stent-graft. 
Although the problem being addressed is the development of a 
new endoprosthesis, the formulation adopted could be used in 
the selection of concepts for other medical devices, and by 
changing some of the quantitative and qualitative parameters, it 
could be used in other products. 
Further research is needed to select the most appropriate 
way to calculate the willingness to pay and the quality of life. 
Furthermore, in this paper, the values of each parameter are not 
presented. However, the success of this concept selection 
technique will depend on the data gathered and used to 
calibrate the model. 
Another issue that should be considered is the formulation 
of the decision problem. In the case of a device that does not 
pose risk to the user and has a short development time, a 
decision tree may be adequate. However, for prostheses, this 
technique may require unrealistic assumptions; in such cases, 
other formulations like real options theory, Bayesian networks 
and Markov networks should be studied. 
More than 10 parameters were suggested to assess each 
concept and the current solutions. This may translate into a 
considerable effort worthwhile only for medical devices whose 
development time is long and requires a big investment. 
ACKNOWLEDGMENTS 
The first author wishes to thank FCT - Fundação para a 
Ciência e Tecnologia, in Portugal, for the financial support 
provided by the grant SFRH/BD/42967/2008. This work is 
partially supported by FCT under the project MIT-Pt/EDAM-
EMD/0007/2008. 
The authors want to thank to Ricardo Valerdi and Richard 
de Neufville for their comments. 
The authors also wish to thank Miguel Marafuz 
(http://illustration-mfz.wordpress.com) for the illustrations. 
REFERENCES 
[1] Pahl G., Beitz W., Feldhusen J., and Grote K.-H., 2007, 
Engineering design - A systematic approach, Springer 
London, London. 
 6 Copyright © 2010 by ASME 
[2] Miller L. C. G., 1993, Concurrent engineering design: 
integrating the best practices for process improvement, 
Society of Manufacturing Engineers. 
[3] King A. M., and Sivaloganathan S., 1999, 
“Development of a methodology for concept selection 
in flexible design strategies,” Journal of Engineering 
Design, 10(4), pp. 329-349. 
[4] Okudan G. E., and Tauhid S., 2009, “Concept selection 
methods a literature review from 1980 to 2008,” 
International Journal of Design Engineering, 1(3), pp. 
243-277. 
[5] El-Haik B., and Mekki K. S., 2008, Medical device 
design for six sigma: A road map for safety and 
effectiveness, John Wiley & Sons, Inc. 
[6] Johnston K. W., Robert B. R., Tilson M. D., Dhiraj M. 
S., Larry H., and James C. S., 1991, “Suggested 
standards for reporting on arterial aneurysms,” Journal 
of Vascular Surgery, 13(3), pp. 452-458. 
[7] Rutherford R. B., 2005, Vascular surgery, Saunders. 
[8] Greenhalgh R. M., 2004, “Comparison of endovascular 
aneurysm repair with open repair in patients with 
abdominal aortic aneurysm (EVAR trial 1), 30-day 
operative mortality results: randomised controlled 
trial,” The Lancet, 364(9437), pp. 843-848. 
[9] Dion Y.-M., and Joseph T., 2010, “Laparoscopic aortic 
surgery,” Peripheral Endovascular Interventions, T.J. 
Fogarty, and R.A. White, eds., Springer New York, pp. 
397-409. 
[10] Katzen B. T., and MacLean A. A., 2006, 
“Complications of endovascular repair of abdominal 
aortic aneurysms: A review,” CardioVascular and 
Interventional Radiology, 29(6), pp. 935-946. 
[11] Milner R., Kasirajan K., and Chaikof E. L., 2006, 
“Future of endograft surveillance,” Seminars in 
Vascular Surgery, 19(2), pp. 75-82. 
[12] Young K. C., Awad N. A., Johansson M., Gillespie D., 
Singh M. J., and Illig K. A., 2010, “Cost-effectiveness 
of abdominal aortic aneurysm repair based on 
aneurysm size,” Journal of Vascular Surgery, 51(1), pp. 
27-32. 
[13] Henderson J., 2008, “Smart textile vascular graft,” 
(11/026 658), p. 11. 
[14] Martinson J. B., Stark J. G., Hanson T. J. B., and 
Backes S. J., 2006, “Instrumented implantable stents, 
vascular grafts and other medical devices,” 
(PCT/US2005/041021), p. 60. 
[15] Kahn K. B., “PDMA Handbook of New Product 
Development (2nd Edition).” 
[16] Matzler K., and Hinterhuber H. H., 1998, “How to 
make product development projects more successful by 
integrating Kanoʼs model of customer satisfaction into 
quality function deployment,” Technovation, 18(1), pp. 
25-38. 
[17] Shah S. G. S., Robinson I., and AlShawi S., 2009, 
“Developing medical device technologies from usersʼ 
perspectives: A theoretical framework for involving 
users in the development process,” International 
Journal of Technology Assessment in Health Care, 
25(04), pp. 514-521.  
 
 7 Copyright © 2010 by ASME 
 
